Clinical Research Of The Correlation Between The CC16 Expression In The Serum And The Severity Of CAP

ObjectiveTo explore the significance of CC16 and the severity in patients with community acquired pneumonia and the possibility of CC16 serving as a diagnostic biomarker of severity for CAP.MethodsNinety-two patients with CAP between Oct.2014 and Oct.2015 in our hospital were enrolled.All patients were divided into low-risk,moderate-risk or high-risk groups according to PSI and CURB-65 score systems,and also divided into non-severe pneumonia group,severe pneumonia group and death group according to the "Guidelines for the diagnosis and treatment of community acquired pneumonia".For PSI score system,there were 33 patient for low-risk group,42 patient for moderate-risk group and 17 for high-risk group,which were 70,13 and 9 for CURB-65 score system,accordingly.For the guideline system,there were 58 patients for non-severe group,28 patients for severe group and 6 patients for death group.Forty healthy controls(20 male and 20 female)were also enrolled.Blood samples were collected in CAP patients and control subjects.The level of CC16 was measured by enzyme-linked immunosorbent assay(ELISA).Results1.92 patients were divided into non-severe group,severe group and death group.The scores of PSI and CURB-65 were highly correlated with the severity of patients.The PSI scores for all 3 groups are 88.64± 11.09,133.45± 14.29 and 161.241±18.06.the CURB-65scores for all 3 groups are 0.93 ± 0.16,1.83 ± 0.74 and 2.81 ± 1.05.The scores of PSI and CURB-65 for death group are significantly higher than that for non-severe group and severe group,which for severe group is also higher than that for non-severe group(P<0.05).2.All patients were divided into low-risk group,moderate-risk group and high-risk group according to PSI score system.The expression of CC16 were down-regulated with more severe pneumonia.The expression levels of all 3 groups are(10.21 ±3.01)μg/L,(8.23±2.05)μg/Land(6.22±1.48)μg/L in the serum of patients.The expression of CC16 in high-risk group is significantly lower than that in moderate and low risk groups,and the CC16 expression in moderate-risk group is lower than that in low-risk group(P<0.05).3.All patients were divided into low-risk group,moderate-risk group and high-risk group according to CURB-65 score system.The correlation between the CC16 expression and the severity by CURB-65 score system is similar to that by PSI scoresystem.The expression levels of all 3 groups are(9.24±2.21)μg/L,(7.26±1.42)μg/L and(5.24±1.48)μg/L in the serum of patients.The expression of CC16 in high-risk group is significantly lower than that in moderate and low risk groups,and the CC16 expression in moderate-risk group is lower than that in low-risk group(P<0.05).4.There was significant negative correlation between the concentration of CC16 expression and PSI score(P<0.05,r=-0.418)and CURB-65 score(P<0.05,r=-0.217).And the correlation between CC16 and PSI score system is better than that between CC16 and CURB-65 score system.5.The CC16 expression in patients before treatment is significantly lower than that in the healthy control people(P<0.05).After treatment,the CC16 is dramatically increased when compared to that before treatment(P<0.05).Conclusion1.The expression of CC16 decreases as the stronger severity of CAP patient,which is also negatively correlated with the PSI/CURB-65 scores.2.The concentration of CC16 in the serum is negatively correlated with the PSI/CURB-65 scores and severity of CAP,which indicates that CC16 might be used as a diagnostic biomarker in the CAP.